Cargando…

Advances in Cardiovascular Biomarker Discovery

Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and its pathological complications pose a major risk for the development of other cardiovascular diseases, including heart failure and stroke. Identifying novel and early stage biomarkers of hypertension...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghantous, Crystal M., Kamareddine, Layla, Farhat, Rima, Zouein, Fouad A., Mondello, Stefania, Kobeissy, Firas, Zeidan, Asad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759775/
https://www.ncbi.nlm.nih.gov/pubmed/33265898
http://dx.doi.org/10.3390/biomedicines8120552
_version_ 1783627176324628480
author Ghantous, Crystal M.
Kamareddine, Layla
Farhat, Rima
Zouein, Fouad A.
Mondello, Stefania
Kobeissy, Firas
Zeidan, Asad
author_facet Ghantous, Crystal M.
Kamareddine, Layla
Farhat, Rima
Zouein, Fouad A.
Mondello, Stefania
Kobeissy, Firas
Zeidan, Asad
author_sort Ghantous, Crystal M.
collection PubMed
description Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and its pathological complications pose a major risk for the development of other cardiovascular diseases, including heart failure and stroke. Identifying novel and early stage biomarkers of hypertension and other cardiovascular diseases is of paramount importance in predicting and preventing the major morbidity and mortality associated with these diseases. Biomarkers of such diseases or predisposition to their development are identified by changes in a specific indicator’s expression between healthy individuals and patients. These include changes in protein and microRNA (miRNA) levels. Protein profiling using mass spectrometry and miRNA screening utilizing microarray and sequencing have facilitated the discovery of proteins and miRNA as biomarker candidates. In this review, we summarized some of the different, promising early stage protein and miRNA biomarker candidates as well as the currently used biomarkers for hypertension and other cardiovascular diseases. Although a number of promising markers have been identified, it is unlikely that a single biomarker will unambiguously aid in the classification of these diseases. A multi-marker panel-strategy appears useful and promising for classifying and refining risk stratification among patients with cardiovascular disease.
format Online
Article
Text
id pubmed-7759775
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77597752020-12-26 Advances in Cardiovascular Biomarker Discovery Ghantous, Crystal M. Kamareddine, Layla Farhat, Rima Zouein, Fouad A. Mondello, Stefania Kobeissy, Firas Zeidan, Asad Biomedicines Review Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and its pathological complications pose a major risk for the development of other cardiovascular diseases, including heart failure and stroke. Identifying novel and early stage biomarkers of hypertension and other cardiovascular diseases is of paramount importance in predicting and preventing the major morbidity and mortality associated with these diseases. Biomarkers of such diseases or predisposition to their development are identified by changes in a specific indicator’s expression between healthy individuals and patients. These include changes in protein and microRNA (miRNA) levels. Protein profiling using mass spectrometry and miRNA screening utilizing microarray and sequencing have facilitated the discovery of proteins and miRNA as biomarker candidates. In this review, we summarized some of the different, promising early stage protein and miRNA biomarker candidates as well as the currently used biomarkers for hypertension and other cardiovascular diseases. Although a number of promising markers have been identified, it is unlikely that a single biomarker will unambiguously aid in the classification of these diseases. A multi-marker panel-strategy appears useful and promising for classifying and refining risk stratification among patients with cardiovascular disease. MDPI 2020-11-30 /pmc/articles/PMC7759775/ /pubmed/33265898 http://dx.doi.org/10.3390/biomedicines8120552 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ghantous, Crystal M.
Kamareddine, Layla
Farhat, Rima
Zouein, Fouad A.
Mondello, Stefania
Kobeissy, Firas
Zeidan, Asad
Advances in Cardiovascular Biomarker Discovery
title Advances in Cardiovascular Biomarker Discovery
title_full Advances in Cardiovascular Biomarker Discovery
title_fullStr Advances in Cardiovascular Biomarker Discovery
title_full_unstemmed Advances in Cardiovascular Biomarker Discovery
title_short Advances in Cardiovascular Biomarker Discovery
title_sort advances in cardiovascular biomarker discovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759775/
https://www.ncbi.nlm.nih.gov/pubmed/33265898
http://dx.doi.org/10.3390/biomedicines8120552
work_keys_str_mv AT ghantouscrystalm advancesincardiovascularbiomarkerdiscovery
AT kamareddinelayla advancesincardiovascularbiomarkerdiscovery
AT farhatrima advancesincardiovascularbiomarkerdiscovery
AT zoueinfouada advancesincardiovascularbiomarkerdiscovery
AT mondellostefania advancesincardiovascularbiomarkerdiscovery
AT kobeissyfiras advancesincardiovascularbiomarkerdiscovery
AT zeidanasad advancesincardiovascularbiomarkerdiscovery